Gene therapy for genetic lipoprotein lipase deficiency: From promise to practice

Netherlands Journal of Medicine

Volumn 63, Issue 1, 2005, Pages 14-19

  Nierman, M C ^a   Rip, J ^a   Twisk, J ^b   Meulenberg, J J M ^b   Kastelein, J J P ^a   Stroes, E S G ^a   Kuivenhoven, J A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Amsterdam Molecular Therapeutics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; NICOTINAMIDE; NICOTINIC ACID DERIVATIVE; OMEGA 3 FATTY ACID; PARVOVIRUS VECTOR; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DIAGNOSTIC TEST; DIET THERAPY; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MEDICAL DECISION MAKING; MONOGENIC DISORDER; NONHUMAN; PANCREATITIS; PREVALENCE; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; XANTHOMA;

ANIMALS; DIET; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN LIPASE; MUTATION; PANCREATITIS; PREVALENCE; RISK FACTORS; XANTHOMATOSIS;

EID: 13444312279     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Olivecrona G, Beisiegel U. Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Arterioscler Thromb Vasc Biol 1997;17(8):1545-9.
2. Taskinen MR, Nikkila EA. High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in man - evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase. Clin Chim Acta 1981;112(3):325-32.
3. Merkel M, Heeren J, Dudeck W, et al. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem 2002;277(9):7405-11.
4. Heeren J, Niemeier A, Merkel M, Beisiegel U. Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo. J Mol Med 2002;80(9):576-84.
5. Milosavljevic D, Kontush A, Griglio S, Le Naour G, Thillet J, Chapman MJ. VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass. Biochim Biophys Acta 2003;1631(1):51-60.
6. Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest 1999;103(12):1697-705.
7. Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation 2002;105(9):1135.
8. Clee SM, Bissada N, Miao F, et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res 2000;41(4):521-31.
9. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99(22):2901-7.
10. Van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Taylor R. Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 2001;157(1):123-9.
11. Gagne SE, Larson MG, Pimstone SN, et al. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin Genet 1999;55(6):450-4.
12. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis 2001;159(2):367-73.
13. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001;60(4):293-300.
14. Myllykangas L, Polvikoski T, Sulkava R, et al. Association of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Ann Med 2001;33(7):486-92.
15. Shimo-Nakanishi Y, Urabe T, Hattori N, et al. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. Stroke 2001;32(7):1481-6.
16. Langlois S, Deeb S, Brunzell JD, Kastelein JJ, Hayden MR. A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. Proc Natl Acad Sci USA 1989;86(3):948-52.
17. Black DM, Sprecher DL. Dietary treatment and growth of hyperchylomicronemic children severely restricted in dietary fat. Am J Dis Child 1993;147(1):60-2.
18. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998;27(3):551-67, viii.
19. Feoli-Fonseca JC, Levy E, Godard M, Lambert M. Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study. J Pediatr 1998;133(3):417-23.
20. Searles GE, Ooi TC. Underrecognition of chylomicronemia as a cause of acute pancreatitis. Can Med Assoc J 1992;147(12):1806-8.
21. Gagne C, Brun LD, Julien P, Moorjani S, Lupien PJ. Primary lipoprotein-lipase-activity deficiency: Clinical investigation of a French Canadian population. Can Med Assoc J 1989;140(4):405-11.
22. Fortson MR, Freedman SN, Webster PD, III. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995;90(12):2134-9.
23. Ohmoto K, Neishi Y, Miyake I, Yamamoto S. Severe acute pancreatitis associated with hyperlipidemia: Report of two cases and review of the literature in Japan. Hepato-Gastroenterology 1999;46(29):2986-90.
24. Sharma P, Lim S, James D, Orchard RT, Horne M, Seymour CA. Pancreatitis may occur with a normal amylase concentration in hypertriglyceridaemia. BMJ 1996;313(7067):1265.
25. Van Walraven LA, de Klerk JBC, Postema RR. Severe acute necrotizing pancreatitis associated with lipoprotein lipase deficiency in childhood. J Pediatr Surg 2003;38(9):1407-8.
26. Nyamugunduru G, Roper H. A difficult case: Childhood onset insulin dependent diabetes presenting with severe hyperlipidaemia. BMJ 1997;314(7073):62.
27. Thompson GR. First priority is to decrease the severity of hyperchylomicronaemia. BMJ 1997;314(7073):62a.
28. Steffes MW, Freier EF. A simple and precise method of determining true sodium, potassium, and chloride concentrations in hyperlipemia. J Lab Clin Med 1976;88(4):683-8.
29. Gagne C, Auger PL, Moorjani S, Brun D, Lupien PJ. Effect of hyperchylomicronemia on the measurement of hemoglobin. Am J Clin Pathol 1977;68(5):584-6.
30. Garrib A, Griffiths W, Eldridge P, Hatton R, Worsley A, Crook M. Artefactually low glycated haemoglobin in a patient with severe hypertriglyceridaemia. J Clin Pathol 2003;56(5):394-5.
31. Ng PC, Lam CWK, Fok TF, et al. Deceptive hyperbilirubinaemia in a new-born with familial lipoprotein lipase deficiency. Journal of Paediatrics and Child Health 2001;37(3):314-6.
32. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992;37:249-73.
33. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Metabolic and molecular basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D, editors. New York: McGraw-Hill, 1995 p. 1913-32.
34. Julien P. High frequency of lipoprotein lipase deficiency in the Quebec population. Can J Cardiol 1992;8(7):675-6.
35. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;(2):213-9.
36. Benlian P, de Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;335(12):848-54.
37. Saika Y, Sakai N, Takahashi M, et al. Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis. Eur J Clin Invest 2003;33(3):216-22.
38. Ebara T, Okubo M, Horinishi A, Adachi M, Murase T, Hirano T. No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61->Stop) in the lipoprotein lipase gene. Atherosclerosis 2001;159(2):375-9.
39. Zambon A, Brunzell JD, Torres A, et al. Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. Lancet 1993;341(8853):1119-21.
40. Ebara T, Ramakristnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein. Eur J Clin Invest 1997;99(11):2672-81.
41. Skarlatos SI, Dichek HL, Fojo SS, Brewer HB, Kruth HS. Absence of triglyceride accumulation in lipoprotein lipase-deficient human monocyte-macrophages incubated with human very low density lipoprotein. J Clin Endocrinol Metab 1993;76(3):793-6.
42. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther 1996;70(2):101-35.
43. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 1998;98(19):2088-93.
44. Durrington P. Dyslipidaemia. Lancet 2003;362(9385):717-31.
45. Vega PhD GL, Grundy MD P. Effect of Statins on Metabolism of Apo-B-Containing Lipoproteins in Hypertriglyceridemic Men. Am J Cardiol 1998;81(1):B36-42.
46. Knopp RH. Drug Treatment of Lipid Disorders. N Engl J Med 1999;341(7):498-511.
47. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989;320(16):1060-8.
48. Demant T, Gaw A, Watts GF, et al. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. J Lipid Res 1993;34(1):147-56.
49. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22(1):24-36.
50. Wang W, Basinger A, Neese RA, et al. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab 2001;280(3):E540-7.
51. Jin FY, Kamanna VS, Kashyap ML. Niacin Accelerates Intracellular ApoB Degradation by Inhibiting Triacylglycerol Synthesis in Human Hepatoblastoma (HepG2) Cells. Arterioscler Thromb Vasc Biol 1999;19(4):1051-9.
52. Jin FY, Kamanna VS, Kashyap ML. Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells: Implication for Reverse Cholesterol Transport. Arterioscler Thromb Vasc Biol 1997;17(10):2020-8.
53. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44(3):455-63.
54. Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984;74(1):82-9.
55. Nozaki S, Garg A, Vega GL, Grundy SM. Postheparin lipolytic activity and plasma lipoprotein response to omega-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia. Am J Clin Nutr 1991;53(3):638-42.
56. Van Dam M, Stalenhoef AFH, Wittekoek J, Trip MD, Prins MH, Kastelein JJP. Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia: A Comparison with Gemfibrozil. Clin Drug Invest 2001;21(3):175-81.
57. Stalenhoef AFH, de Graaf J, Wittekoek ME, Bredie SJH, Demacker PNM, Kastelein JJP. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia. Atherosclerosis 2000;153(1):129-38.
58. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4(5-6):385-91.
59. Richter WO, Jacob BG, Ritter MM, Schwandt P. Treatment of primary chylomicronemia due to familial hypertriglyceridemia by omega-3 fatty acids. Metabolism 1992;41(10):1100-5.
60. Pschierer V, Richter WO, Schwandt P. Primary chylomicronemia in patients with severe familial hypertriglyceridemia responds to long-term treatment with (n-3) fatty acids. J Nutr 1995;125(6):1490-4.
61. Excoffon KJDA, Liu G, Miao L, et al. Correction of Hypertriglyceridemia and Impaired Fat Tolerance in Lipoprotein Lipase Deficient Mice by Adenovirus-Mediated Expression of Human Lipoprotein Lipase. Arterioscler Thromb Vasc Biol 1997;17(11):2532-9.
62. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24(3):257-61.
63. Ross CJ, Twisk J, Meulenberg JM, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum Gene Ther 2004;15(9):906-19.